A commitment to
rapid drug development
and community focus

Our mission at Tikun Therapeutics, a registered Public Benefit Corporation (PBC), is to aggressively drive drug development for the ultra-rare and progressive genetic disease familial dysautonomia (FD), one of many rare diseases currently underserved by pharmaceutical companies. As its unwavering focus, and working with transparency in concert with its stakeholders, Tikun will ensure unfettered access to any approved drugs for the FD community at the lowest possible cost.